Waldron Private Wealth LLC Sells 230 Shares of Becton, Dickinson and Company (NYSE:BDX)

Waldron Private Wealth LLC trimmed its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 15.5% in the third quarter, according to its most recent filing with the SEC. The firm owned 1,253 shares of the medical instruments supplier’s stock after selling 230 shares during the period. Waldron Private Wealth LLC’s holdings in Becton, Dickinson and Company were worth $302,000 as of its most recent filing with the SEC.

Several other institutional investors have also made changes to their positions in the business. RBA Wealth Management LLC acquired a new stake in Becton, Dickinson and Company during the third quarter valued at approximately $4,997,000. Eastern Bank lifted its position in shares of Becton, Dickinson and Company by 1,746.9% during the 3rd quarter. Eastern Bank now owns 18,377 shares of the medical instruments supplier’s stock worth $4,431,000 after buying an additional 17,382 shares during the period. Sequoia Financial Advisors LLC boosted its stake in Becton, Dickinson and Company by 15.6% in the 3rd quarter. Sequoia Financial Advisors LLC now owns 5,705 shares of the medical instruments supplier’s stock valued at $1,376,000 after buying an additional 770 shares in the last quarter. Graybill Wealth Management LTD. grew its position in Becton, Dickinson and Company by 0.8% in the third quarter. Graybill Wealth Management LTD. now owns 17,530 shares of the medical instruments supplier’s stock valued at $4,227,000 after acquiring an additional 139 shares during the period. Finally, Oakworth Capital Inc. raised its stake in Becton, Dickinson and Company by 3.3% during the third quarter. Oakworth Capital Inc. now owns 1,708 shares of the medical instruments supplier’s stock worth $412,000 after acquiring an additional 54 shares in the last quarter. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have recently weighed in on BDX. Raymond James lowered their target price on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a report on Friday, August 2nd. Evercore ISI raised their price objective on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. Citigroup raised Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $255.00 to $275.00 in a report on Tuesday, October 1st. StockNews.com raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Finally, Stifel Nicolaus boosted their price objective on Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a research note on Friday, July 26th. Nine research analysts have rated the stock with a buy rating, According to data from MarketBeat, Becton, Dickinson and Company has an average rating of “Buy” and an average target price of $282.63.

Becton, Dickinson and Company Stock Up 0.3 %

NYSE BDX opened at $240.52 on Thursday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.36 and a current ratio of 1.85. Becton, Dickinson and Company has a 52 week low of $218.75 and a 52 week high of $262.23. The stock has a market capitalization of $69.51 billion, a P/E ratio of 52.98, a price-to-earnings-growth ratio of 1.79 and a beta of 0.42. The stock has a fifty day moving average of $237.33 and a 200-day moving average of $235.16.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share for the quarter, topping the consensus estimate of $3.31 by $0.19. Becton, Dickinson and Company had a return on equity of 14.49% and a net margin of 7.13%. The firm had revenue of $4.99 billion during the quarter, compared to analysts’ expectations of $5.08 billion. During the same period in the previous year, the business posted $2.96 EPS. The company’s quarterly revenue was up 2.3% compared to the same quarter last year. On average, equities research analysts forecast that Becton, Dickinson and Company will post 13.11 EPS for the current year.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.